- Policy
- 5-year relative survival rate of cancer 72.1% in 2021
- by Lee, Jeong-Hwan Jan 2, 2024 05:45am
- The five-year relative survival rate for cancer patients increased by 6.6% points in 10 years and has become 72.1%. In Korea, thyroid cancer was the most common, followed by colorectal, lung, and stomach cancers. On December 28th, the Ministry of Health and Welfare (Minister Kyoo-Hong Cho) and the Central Cancer Registry Cancer (National Can
- Policy
- Revising the PE exemption system… focuses on 'deferral'
- by Lee, Tak-Sun Jan 2, 2024 05:44am
- The ‘Pharmacoeconomic Evaluation Exemption System', which was first implemented in 2015, will be completely transformed in the new year. In the future, the system will defer rather than exempt companies from submitting required data, increasing the possibility of drugs being evaluated after listing. According to the industry on Dece
- Policy
- Peramiflu shortages may require gov. intervention
- by Lee, Tak-Sun Dec 29, 2023 05:39am
- The government is poised to implement supply control of Peramiflu inj., an injection for transfusion, following the management of oral influenza treatment, Tamiflu. Peramiflu inj. is experiencing out-of-stock in medical services due to a recent increase in demand. Health Insurance Review and Assessment Service (HIRA)’s Korea Pharmace
- Policy
- True Set, a triple hypertension therapy, to face generics
- by Lee, Tak-Sun Dec 28, 2023 06:02am
- Generics of Yuhan’s True Set Tab., a triple-combination drug for hypertension with rapid sales growth, are already gearing up for competition. True Set, a triple-combination drug that contains telmisartan, amlodipine besylate, and chlorthalidone, received approval in August 2019. Subsequently, True Set was released to the market in Nov
- Policy
- Reform should drive development of 2 homegrown blockbusters
- by Lee, Jeong-Hwan Dec 27, 2023 06:03am
- The government expressed the will to encourage pharmaceutical companies to invest in research and development (R&D) and secure the momentum of developing two homegrown blockbuster drugs through the reform of the drug pricing system to reflect innovative value. Above all, the government has made it clear that it will strengthen the sustainabil
- Policy
- Swiss’s Idorsia applies for the reimb of its first product
- by Lee, Tak-Sun Dec 27, 2023 06:03am
- The Korean subsidiary of the Swiss pharmaceutical company Idorsia has started the reimbursement process for the drug upon receiving approval for Pivlaz Inj (clazosentan sodium). The drug, which is used to prevent cerebral vasospasm, is expected to be sold by Handok in Korea, with the company also conducting domestic clinical trials. Ac
- Policy
- Enhertu, G-tec will benefit from new govn't plan
- by Lee, Tak-Sun Dec 26, 2023 05:47am
- According to the ‘Plan for the compensation of the innovative value of new drugs’ that the government announced on the 22nd, the breast cancer treatment ‘Enhertu (Daiichi Sankyo-AstraZeneca),’ and the new gastrointestinal botanical drug ‘G-tec (Chong Kund Dang)’ are being regarded as immediate beneficiaries. In the case of Enhertu,
- Policy
- Series of expectorant Prospan generics enter KOR mkt
- by Lee, Tak-Sun Dec 22, 2023 05:46am
- Generic versions of Prospan Syrup, a drug that dominated the phyto-expectorant market in the 2000s, are again being introduced to the market. Prospan Syrup, which has been resold by Kwangdong Pharmaceutical since 2012, is the only available 200mL bottle formulation of Prospan, and 7.5mL and bottle formulations of the drug are only availa
- Policy
- Delayed re-evaluation of hyaluronic acid eye drops
- by Lee, Tak-Sun Dec 21, 2023 05:54am
- The re-evaluation of the reimbursement appropriateness of hyaluronic acid (HA) eye drops has ultimately been delayed. On the 7th, the Health Insurance Review and Assessment Service (HIRA)’s Drug Reimbursement Committee decided to conduct an additional review of the re-evaluation item. Similarly, on the 20th, the Ministry of Health and W
- Policy
- Braftovi Cap. & Bosulif tablets reimb for the New Year
- by Lee, Tak-Sun Dec 21, 2023 05:39am
- Starting on Jan 1 next month, two anti-cancer drugs will be reimbursed. These drugs include Ono Pharmaceutical Korea’s Braftovi Cap. 75mg (encorafenib) and the 3 Pfizer Korea’s Bosulif tablet tiems. Braftovi has been listed following drug price negotiation with the National Health Insurance Service, and Bosulif was not subject to maximum
